enicepatide vs HDM1005
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
enicepatide
Developed by Roche and partners
NCT06525935 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
Reported efficacy
Percent Change in Body Weight from Baseline to Week 48: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) (met)
Result source: NCT06525935
HDM1005
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07502001 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | enicepatide | HDM1005 |
|---|---|---|
| Body weight, % change | —Trial running · NCT07670416 | —Trial running · NCT07279194 |
| Weight loss of 5% or more | —Trial running · NCT07670416 | —Trial running · NCT07279194 |
| Weight loss of 10% or more | —Trial running · NCT07670416 | —Trial running · NCT07279194 |
| Waist circumference, change (cm) | —Trial running · NCT07670416 | —Trial running · NCT07279194 |
Body weight, % change
- enicepatide
- —Trial running · NCT07670416
- HDM1005
- —Trial running · NCT07279194
Weight loss of 5% or more
- enicepatide
- —Trial running · NCT07670416
- HDM1005
- —Trial running · NCT07279194
Weight loss of 10% or more
- enicepatide
- —Trial running · NCT07670416
- HDM1005
- —Trial running · NCT07279194
Waist circumference, change (cm)
- enicepatide
- —Trial running · NCT07670416
- HDM1005
- —Trial running · NCT07279194
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HDM1005: no structured comparison results are available for Obesity.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: enicepatide's landscape · HDM1005's landscape